RT Journal Article
T1 Cytomegalovirus reactivation in patients diagnosed with severe COVID-19: A point prevalence study in a general hospital
A1 Pérez Granda, María Jesús
A1 Muñoz García, Patricia Carmen
A1 García Martínez, Rita
A1 Villalba García, María Victoria
A1 Puente Maestu, Luis
A1 Bouza Santiago, Emilio
AB PurposeTo determine the prevalence of CMV reactivation in a population admitted for severe COVID-19 to a general hospital.MethodsPoint prevalence study in all hospitalized patients with severe COVID-19 (admitted either to general wards or ICU). Determination of the presence of CMV DNA in circulating blood. COVID-19 was confirmed in patients with compatible clinical manifestations, usually with pneumonia and a positive nasopharyngeal PCR test.ResultsWe included 140 hospitalized patients with COVID-19 who consented to participate. A total of 16 patients (11.42%), had circulating CMV-DNA in peripheral blood at the time of the study. Patients with positive CMV viral load were mainly ICU patients (11/37 -29,7%) and only 5/103 cases (4,85%) were hospitalized into general wards. The accumulated doses of corticosteroids (prednisone equivalents) in the study day were (median and IQR) 987.50 mg (396.87-2,454.68) and 187.50 mg (75.00-818.12) respectively in CMV positive and negative patients (p < 0.001). A significant proportion of CMV positive patients were discovered because of the study and were clinically unsuspected by their physicians. The coin-fected COVID-CMV positive population had a higher risk of accumulated secondary nosocomially-acquired infections and a worse prognosis.ConclusionCMV reactivation should be systematically searched in patients in COVID-19 cases admitted to the ICU.
PB Sociedad Española de Quimioterapia
SN 0214-3429
YR 2023
FD 2023-02-01
LK https://hdl.handle.net/20.500.14352/115708
UL https://hdl.handle.net/20.500.14352/115708
LA eng
NO Pérez-Granda MJ, Catalán P, Muñoz P, Aldámiz T, Barrios JC, Ramírez C, García-Martínez R, Villalba MV, Puente L, Bouza E. Cytomegalovirus reactivation in patients diagnosed with severe COVID-19: A point prevalence study in a general hospital. Rev Esp Quimioter. 2023 Feb;36(1):45-51. doi: 10.37201/req/068.2022. Epub 2022 Nov 22. PMID: 36408974; PMCID: PMC9910675.
NO Fondos FEDER
NO European Commission
NO Centro de Investigación Biomédica en Red Enfermedades Respiratorias  (CIBERES)
DS Docta Complutense
RD 6 abr 2025